» Articles » PMID: 38576514

Impact of Prior SARS-CoV-2 Infection on College Students' Hesitancy to Receive Additional COVID-19 Vaccine Booster Doses: A Study from Taizhou, China

Overview
Journal Prev Med Rep
Date 2024 Apr 5
PMID 38576514
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study aimed to examine the impact of a history of SARS-CoV-2 infection on the hesitancy of college students to receive additional COVID-19 vaccine booster doses.

Methods: A population-based self-administered online survey was conducted in July 2024 in Taizhou, China. A total of 792 respondents were included in this study. Logistic regression was conducted to identify factors associated with college students' hesitation to receive booster doses of the COVID-19 vaccine.

Results: Of 792 respondents, 32.2 % hesitated to receive additional doses of the COVID-19 vaccine booster. Furthermore, 23.5 % of the respondents reported an increase in hesitancy to receiving additional COVID-19 vaccine booster doses compared to before they were infected with SARS-CoV-2. In the regression analyses, college students who had a secondary infection were more hesitant to receive additional COVID-19 vaccine booster doses (OR = 0.481, 95 % CI: (0.299-0.774), P = 0.003). Moreover, students with secondary infections who were male (OR = 0.417, 95 % CI: 0.221-0.784, P = 0.007), with lower than a bachelor's degree (OR = 0.471, 95 % CI: 0.272-0.815, P = 0.007), in non-medical majors (OR = 0.460, 95 % CI: 0.248-0.856, P = 0.014), and sophomores or below (OR = 0.483, 95 % CI: 0.286-0.817, P = 0.007) were more hesitant to receive additional COVID-19 vaccine booster doses.

Conclusion: A history of SARS-CoV-2 infection affects college students' hesitation to receive additional COVID-19 vaccine booster doses, which was higher in those who experienced secondary infections.

References
1.
Liu Y, Xu Y, Wang J, Che X, Gu W, Du J . Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups. Hum Vaccin Immunother. 2020; 17(1):157-161. PMC: 7872049. DOI: 10.1080/21645515.2020.1765620. View

2.
Dube E, Gagnon D, Nickels E, Jeram S, Schuster M . Mapping vaccine hesitancy--country-specific characteristics of a global phenomenon. Vaccine. 2014; 32(49):6649-54. PMC: 5355208. DOI: 10.1016/j.vaccine.2014.09.039. View

3.
Liu Y, Kuang K . Predictors of COVID-19 vaccination hesitancy in China: a meta-analysis. Public Health. 2023; 220:135-141. PMC: 10186963. DOI: 10.1016/j.puhe.2023.05.009. View

4.
Wong J, Yang J . Misinformation, Anticipated Regret, and Vaccine-Related Behaviors. J Health Commun. 2022; 27(9):644-653. DOI: 10.1080/10810730.2022.2148022. View

5.
Klugar M, Riad A, Mohanan L, Pokorna A . COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study. Vaccines (Basel). 2021; 9(12). PMC: 8705445. DOI: 10.3390/vaccines9121437. View